BioCryst Pharma (NASDAQ:BCRX) reported its Q1 earnings results on Wednesday, May 3, 2023 at 07:00 AM.
Here’s what investors need to know about the announcement.
Earnings
BioCryst Pharma beat estimated earnings by 6.67%, reporting an EPS of $-0.28 versus an estimate of $-0.3.
Revenue was up $18.86 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.21 which was followed by a 13.08% increase in the share price the next day.
Here’s a look at BioCryst Pharma’s past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.17 | -0.28 | -0.34 | -0.37 |
| EPS Actual | -0.38 | -0.23 | -0.32 | -0.40 |
| Revenue Estimate | 75.64M | 75.23M | 64.31M | 51.36M |
| Revenue Actual | 79.55M | 75.83M | 65.53M | 49.92M |
To track all earnings releases for BioCryst Pharma visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
